We’re excited to share that the FDA has accepted our New Drug Application for our potential next-in-class cardiac myosin inhibitor in adult patients with obstructive hypertrophic cardiomyopathy (HCM). Learn more here: https://bit.ly/3ZwXczg #HCM
Cytokinetics
Biotechnology Research
South San Francisco, California 28,256 followers
Empowering Muscle Empowering Lives
About us
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
- Website
-
http://www.cytokinetics.com
External link for Cytokinetics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 1998
- Specialties
- Heart Failure, Amyotrophic Lateral Sclerosis, and Hypertrophic Cardiomyopathy
Locations
-
Primary
Get directions
350 Oyster Point Blvd
South San Francisco, California 94080, US
Employees at Cytokinetics
-
Christopher Brey
Senior Director, Facilities and EHS
-
Brett Pletcher
Chief Legal Officer, Cytokinetics; Life Sciences and Public Company Advisor, Gunderson Dettmer; and Former General Counsel at Gilead Sciences
-
Stefan Engst
Principal Scientist at Cytokinetics
-
Kapil Menghrajani
Biopharmaceutical and Medical Diagnostic Professional
Updates
-
2024 was a year in our history marked by many incredible accomplishments thanks to our dedicated and ambitious team. This year, alongside advancements in our pipeline and progress made on our mission, we continued to live our values and sustain a culture driven by patient-centricity, dedication to science, diversity, laughter and collaboration. We have much to be proud of in 2024. 2025, we’re ready for you!
-
Yesterday, we hosted our first-ever patient day and invited 20 #HCM patients along with care partners and patient advocacy leaders for a day filled with activities, discussions, connection, and purpose. We named the event Polaris, which is the astronomical name for the North Star, symbolic of our core value: Patients are our North Star. At Polaris, we held numerous activities ranging from patients sharing their stories with employees to breakout sessions focused on key topics to patient advocacy organization leaders providing perspectives and opportunities to support their missions. Polaris affirmed our commitment to our mission and the importance of understanding the patient journey and connecting with the community. Learn more about our advocacy efforts: https://bit.ly/3D5qr3K #PatientAdvocacy
-
We are pleased to be starting COMET-HF, a confirmatory Phase 3 clinical trial for patients with symptomatic heart failure (HF) with severely reduced ejection fraction. Read more: https://bit.ly/3Zm4t3G #HeartFailure
-
-
Today we announced that we will participate in upcoming investor conferences hosted by Evercore and Piper Sandler. https://bit.ly/3ZAVdtK
-
-
We announced an exclusive licensing collaboration with Bayer for the development and commercialization of our investigational cardiac myosin in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). https://bit.ly/4eGbgen #HCM
-
-
We announced additional data related to our investigational cardiac myosin activator presented at #AHA24. Learn more here: https://bit.ly/40MEuVD #HeartFailure
-
-
Today is our industry theater presentation at #AHA24, “Navigating the Complexities of Hypertrophic Cardiomyopathy: Addressing Delayed Diagnosis, Disease Burden, and Shared Decision-Making.” Learn more here: https://bit.ly/3Um7hvW #HCM
-
-
Today we announced new data related to our investigational cardiac myosin inhibitor presented at #AHA24. Learn more here: https://bit.ly/3AGz7N5 #HCM
-
-
It’s Native American Heritage month, and we’re taking the opportunity to honor the traditions and histories of Native American communities. Today, our colleague Brandy Camps from our Talent Acquisition team shares about her tribe, the Chitimacha Tribe. #NativeAmericanHeritageMonth